enGene Highlights Surfactant-Enhanced Bladder Cancer Therapy Data and 2027 Update PathMarketBeat · Oct 16, 2026
enGene Therapeutics Inc. (ENGN) Discusses Preclinical Data and Clinical Case Studies on Incorporating Surfactant Bladder Rinse into Treatment TranscriptSeeking Alpha · Oct 15, 2026
enGene to Host KOL Webinar on October 15, 2026Business Wire · Oct 13, 2026
enGene Therapeutics Inc. (ENGN) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking Alpha · Sep 14, 2026
enGene Therapeutics: Slashing Cash Burn To Bring Their Asset To The MarketSeeking Alpha · Sep 10, 2026
enGene Reports Third Quarter 2026 Financial Results and Provides Business UpdateBusiness Wire · Sep 8, 2026Operating through its subsidiary, enGene, Inc., enGene Holdings Inc. functions as a clinical-stage biotechnology firm. Its core mission involves pioneering genetic pharmaceuticals, achieved by administering therapeutic agents directly to mucosal tissues and other bodily organs. A key asset in its pipeline is EG-70, also known as detalimogene voraplasmid.
| Date | Est. | Actual | |
|---|---|---|---|
| Sep 8, 2026 | -$0.43 | -$0.47 | Miss |
| Jun 15, 2026 | -$0.48 | -$0.43 | Beat |
| Mar 9, 2026 | -$0.55 | -$0.44 | Beat |
| Dec 22, 2025 | -$0.57 | -$0.73 | Miss |
| Sep 11, 2025 | -$0.50 | -$0.57 | Miss |
| Jun 12, 2025 | -$0.50 | -$0.51 | Miss |